A purity figure of 98.6% is only as trustworthy as the procedure that produced it. Before a laboratory relies on an HPLC method to report the purity of a synthetic peptide, it is expected to show, with planned experiments and written acceptance criteria, that the method measures what it claims to measure. That exercise is called analytical method validation, and the vocabulary most laboratories use for it comes from the ICH Q2 guideline.
ICH Q2 was written for regulated pharmaceutical work, but its terms have become the common language of analytical chemistry. Knowing what each one means makes it much easier to judge a validation summary, a method description or a claim that a result is “validated.”
Where ICH Q2 comes from and what it asks for
The International Council for Harmonisation publishes Q2 as a guideline on validating analytical procedures. The long-standing version, Q2(R1), listed a set of performance characteristics and indicated which ones apply to which type of test. A revision, Q2(R2), was finalized in 2023 alongside a companion guideline on analytical procedure development, ICH Q14.
For a purity method, the relevant categories are a quantitative test for impurities and, where the main peak is measured against a reference, an assay. The characteristics that matter most for both are specificity, linearity and range, accuracy and precision.
Specificity: can the method tell the peptide from its neighbors?
Specificity is the ability to measure the analyte unequivocally in the presence of things that are expected to be there: synthesis by-products such as deletion sequences, degradation products, counter-ion peaks and anything contributed by the sample diluent. For a peptide purity method this is the characteristic that matters most, because an impurity hidden under the main peak inflates the reported purity without any visible sign.
Laboratories usually demonstrate specificity in three ways. They run a blank to show the diluent contributes no interfering peaks. They analyze deliberately stressed material to show that degradation products separate from the main peak, the approach described in our article on forced degradation and stability-indicating methods. And they check the main peak for hidden components, with diode-array spectra or mass spectrometry. The limits of those checks are covered in co-elution and peptide purity.
Linearity and range for a peptide purity assay
Linearity asks whether detector response is proportional to the amount of analyte over the concentrations the method will actually meet. Q2(R1) recommends at least five concentration levels. The data are fitted by least-squares regression and the report states the slope, the y-intercept, the correlation coefficient and a plot of residuals. A curved residual plot can reveal detector saturation that a high correlation coefficient hides.
Range is the interval between the lowest and highest concentrations for which linearity, accuracy and precision have all been shown to be acceptable. Commonly cited minimum ranges are 80 to 120% of the test concentration for an assay, and from the reporting level of an impurity up to 120% of its specification for an impurity test. For area-percent purity this matters in a specific way: the method must respond linearly both at the large main peak and at the small impurity peaks, which can differ in size by a factor of several hundred.
Accuracy: closeness to the true value
Accuracy describes how close a measured result comes to a value accepted as true. It is usually established by analyzing samples of known content, most often a characterized reference standard or a sample spiked with a known amount of analyte, and expressing the result as percent recovery. Q2(R1) recommends a minimum of nine determinations over at least three concentration levels spanning the range, for example three replicates at each of three levels.
For impurities, accuracy is often shown by spiking known impurities into the main material. Where impurity standards are unavailable, as is common for peptide by-products, laboratories may compare against a second, independent procedure instead. The quality of any accuracy claim depends on the reference material behind it, which is why reference standard traceability is part of the same discussion.
Precision at three levels
Precision describes how closely repeated measurements of the same homogeneous sample agree, and it is normally reported as a relative standard deviation. Q2 separates it into three levels:
| Level | What varies | Typical design |
|---|---|---|
| Repeatability | Nothing deliberately; same analyst, instrument and day | At least 6 determinations at 100% of test concentration, or 9 across the range |
| Intermediate precision | Days, analysts or instruments within one laboratory | Planned variation of those factors |
| Reproducibility | Laboratories | Collaborative or inter-laboratory study |
Precision and accuracy are independent. A method can return nearly identical results every time and still be biased, and a method with an unbiased average can scatter widely around it. A validation summary that reports only repeatability says little about how the figure would move on another day or in another analyst’s hands. The spread that remains after validation is the starting point for estimating measurement uncertainty in peptide purity.
Limits, robustness and the daily check
For impurity methods, validation also establishes the quantitation limit, the smallest amount that can be measured with acceptable accuracy and precision, and often the detection limit. Robustness examines how sensitive the result is to small, deliberate changes such as column temperature, mobile-phase pH or gradient slope. The outcome of robustness work usually feeds the system suitability criteria that are checked before each sequence. Validation shows a method can work; system suitability shows it did work on the day.
What “validated” should mean on a report
The word is easy to print and hard to evaluate without detail. A meaningful claim identifies the characteristics studied, the acceptance criteria set in advance and the outcome against each one. It also states the scope: a method validated for one peptide at one concentration is not automatically validated for a related sequence. Research-grade testing is frequently performed with methods that are well developed and qualified for their purpose without a full Q2 package, and that is not in itself a defect, provided the report does not imply otherwise.
Every Battle Born listing carries its own independent reverse-phase HPLC result, posted with the product, and the vial is identified against that result by its crimp and cap color rather than by lot numbers. The published chromatogram and method conditions are what a reader can examine with the characteristics above in mind.
Frequently asked questions
Is ICH Q2 a legal requirement for research-grade peptide testing?
No. It is a guideline that regulators apply to pharmaceutical submissions. Outside that setting it serves as a widely recognized reference for what a validation study should cover.
What is the difference between specificity and selectivity?
The terms are often used interchangeably. Q2 has historically used specificity; many analytical chemists prefer selectivity, because few methods respond to one substance alone.
Why is a correlation coefficient of 0.999 not enough to prove linearity?
A high r value can coexist with systematic curvature or a large intercept. Residual plots and the intercept relative to the response at the target level reveal what r alone conceals.
Does a validated method ensure a correct result every time?
Validation shows the method is capable under defined conditions. Each run still depends on system suitability, correct sample handling and sound peak integration.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.